Jiangsu Feiyu Pharmaceutical Technology Co., Ltd.

Jiangsu Feiyu Pharmaceutical Technology Co., Ltd. was established in November 2006 and completed the shareholding system reform in April 2021.

The company focuses on the research and development, production and sales of medicine and pesticide intermediate. Adhering to the "environmental protection priority, safety first, saving energy and reducing consumption, continuous innovation, science and technology and rejuvenating the country" business philosophy, relying on the automatic, continuous, large-scale mature production system, Feiyu Pharmaceutical dedicates to the development of green, energy saving, high efficiency and safety of innovative production technology, providing the high quality fine chemical products for medicine, pesticide and other downstream applications.

Main products of Feiyu Pharmaceutical includes 2,4-dichloro-5-fluorobenzoyl chloride, Ethyl 3-(N,N-dimethylamino) acrylate , Ethyl 3-(cyclopropylamino)-2-(2,4-dichloro-5-fluorobenzoyl) acrylate and Cyclopropylamine, widely used in medicine and pesticide fields.

Feiyu Pharmaceutical is High-Tech Enterprise, Specialized, Fined, Peculiar and Innovative SME in Jiangsu Province，Gazelle Enterprise in Sunan National Innovation Park, Pilot Enterprise of Jiangsu Integration of Information and Integration Management System, and also is Three-Star Enterprise in Changzhou City.

We focus on the research, development, production and sales of medicine and pesticide intermediate

The company always adheres to the development strategy of innovation, and is committed to the development of green, energy saving, efficient and safe innovative production processes. Through self-research or cooperation with scientific research institutions such as Dalian University of Technology Jiangsu Research Institute, Changzhou University, combined with the test results of small-scale development and scale-up verification, the company constantly improves product yield and reduces production costs.

Until the end of June 2024, Feiyu Pharmaceutical has 51 utility model patents and 15 invention patents, forming the company's independent intellectual property system. The company's quinolone special chemicals and active compounds engineering technology research center has been approved to be built as a Jiangsu Province engineering technology research center. Feiyu Pharmaceutical now masters several core techniques to realize the automatic control of production process, through continuous scientific and technological innovation to develop the advanced process of green cycle production, forming a strong competitive advantage.

The company has a production base of about 31,000 square meters in Changzhou, Jiangsu province, and has started to lay out a modern production base of about 118,700 square meters in Shangrao, Jiangxi Province. The company has formulated a plan to expand the production of existing products, extend the industrial chain vertically and horizontally, and has broad prospects for future development.

Company Profile

Jiangsu Feiyu Pharmaceutical Technology Co., Ltd. is a private enterprise established in November 2006.According to the requirements of technical specifications, laws and regulations, from June 2016 to September 2017, we invested a total of 137 million yuan to comprehensively improve and upgrade our production facilities. Newly built three new core competitiveness of 2,4-dichloro-5-fluorobenzoyl chloride, N,N-dimethylamino ethyl acrylate, 3-cyclopropylamino-2-(2,4-dichloro-5-fluoro-benzoyl)-ethyl acrylate Special specialty chemicals project. The three products mentioned above have a wide range of uses, and our market share has been steadily expanding. Most of our clients are domestic central-owned enterprises, listed companies and well-known global chemical companies. There are two peer companies to produce similar products in the world, and we are a leader in the special medical chemicals segment. In 2020, we were listed as a “Gazelle Enterprise” in Southern Suzhou National Independent Innovation Demonstration Zone.

In recent years, we have continuously strengthened the development of new products and improved safety and environmental protection while still maintaining sound economic benefits. During the four years from 2016 to 2019, our annual sales revenue had increased by more than 50% and the tax paid increased by more than 100% each year. In 2020, we realized an operating income of about 400 million yuan, a paid tax of more than 30 million yuan, and a realized profit of more than 70 million yuan.

We focus on the research, development, production and sales of upstream intermediates of quinolone APIs, and has gathered a group of experienced scientific and technological talents and management talents. We have been leading the world in design and exploration of main synthesis and amplification routes of quinolones, process optimization, development of new production routes, and other aspects.

Boasting advanced production technologies, perfect testing methods, we maintain close cooperation with universities and research institutes. We have passed ISO9001 and ISO14001 quality and environmental system certification, won the title of “national high-tech enterprise”, and have been rated as a contract-honoring and trustworthy enterprise in a row.

After a full analysis of the internal and external environment and make arrangements beforehand to seize opportunities in the industry, we decided to go out of Jiangsu and purchased a plot of 200mu with a total investment of 650 million yuan in the picturesque and business-clustering Sulphur Chemical Industry Park in Dexing, Shangrao, Jiangxi Province. The land was used for the construction of the quinolone specialty chemical and active compound project with a production capacity of 29,000 tons per year. We insist in building the green industrial chain for key intermediates of quinolone APIs, strive to integrate internal resources of all kinds to form an economic circle and contribute to the high-quality development of the regional economy. By doing so, we became a vivid industrial practice for the “Two Mountain Theory” proposed by the General Secretary Xi Jinping.

The company will give full play to its own advantages, adhering to the corporate philosophy of "environmental protection priority, energy saving and consumption reduction, continuous innovation", continue to carry out technological innovation, equipment innovation, service innovation, and management innovation, and continue to develop more special pharmaceutical chemicals for future development. Promote the progress of my country's pharmaceutical raw material medicine industry.